Navigation Links
OPAXIO(TM) Combined with Alimta(R) Well Tolerated in Dose-Ranging Study of Patients with Advanced Non-Small Cell Lung Cancer
Date:8/2/2009

SEATTLE, Aug. 3 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced results from a study released by Dartmouth-Hitchcock Medical Center at the International Association for the Study of Lung Cancer (IASLC) 13th World Conference on Lung Cancer. The study demonstrated that in patients with advanced non-small cell lung cancer (NSCLC), the combination of OPAXIO (paclitaxel poliglumex) and Alimta(R) (pemetrexed) was well tolerated and resulted in median progression-free survival of 3.3 months.

The study, led by Dr. J. R. Rigas, enrolled twelve patients, six to each of two dose levels. Patients were treated in 21-day cycles, with cohort one receiving 135 mg/m2 of paclitaxel poliglumex and 500 mg/m2 of pemetrexed, and cohort two receiving 175 mg/m2 of paclitaxel poliglumex and 500 mg/m2 of pemetrexed. None of the patients in cohort one had an initial dose-limiting toxicity (IDLT) with two cycles of therapy. There was one IDLT of infection with neutropenia in cohort two. Aside from grade 3 fatigue in two patients, there were no grade 3 or greater nonhematologic toxicities. A median of 4.5 cycles was delivered in each cohort.

The best response was stable disease in nine patients. Two patients remain without evidence of disease progression, and six patients were alive at time of data presentation. Median progression free survival was 3.3 months.

This poster is available at www.celltherapeutics.com/investor_updates

About (product)

OPAXIO(TM) (paclitaxel poliglumex, CT-2103), which was formerly known as XYOTAX(TM), is an investigational, biologically enhanced, chemotherapeutic that links paclitaxel, the active ingredient in Taxol(R), to a biodegradable polyglutamate polymer, which results in a new chemical entity. When bound to the polymer, the chemotherapy is rendered inactive, potentially sparing normal tissue
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Complete Study Results Comparing CTIs OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology
2. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
3. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
4. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
5. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
6. RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
7. Multi-Centre European Clinical Trial Shows Advanced Dysplasia and Early Cancer of Esophagus Cured With Combined Endoscopic Resection and Radiofrequency Ablation With HALO Ablation System
8. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
9. Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinsons Disease
10. Study Shows VAPRISOL(R) is Effective in Increasing Serum Sodium Levels and Well-Tolerated in Patients With Euvolemic or Hypervolemic Hyponatremia
11. IDM Pharma Announces IDM-2101 Updated Phase 2 Results Show Treatment Well Tolerated With Positive Survival Trend in Lung Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 27, 2015  The quality function within the medical ... meet quality standards at every stage of the product ... leaders also have the challenge of balancing quality and ... who don,t effectively balance these priorities risk funding and ... failure and regulatory scrutiny. For the third ...
(Date:3/27/2015)... , March 27, 2015 Levi & ... Pharmaceutical, Inc. (NASDAQ: OHRP ) concerning possible violations ... issued by the Company in connection with its study ... TO: http://zlk.9nl.com/ohr-pharmaceutical-ohrp or contact Joseph E. ... or by telephone at (212) 363-7500, toll-free: (877) ...
(Date:3/27/2015)... March 27, 2015 /PRNewswire/ - Medicure Inc. (the "Company") ... has approved the grant of an aggregate of 236,070 ... and consultants of the Company pursuant to the Company,s ... to expire on the tenth anniversary of the date ... third anniversary of the date of grant and 50,000 ...
Breaking Medicine Technology:New Medical Device Quality Study Finds Regulatory Environment is Boosting Quality Spending, Especially for Large Companies 2
... Pa., July 28, 2011 Kensey Nash Corporation (Nasdaq: ... earnings results for its fourth quarter and fiscal year ended ... August 18, 2011.   Joe Kaufmann, President and ... on Thursday, August 18, 2011 at 9:00 A.M. Eastern Time. ...
... 2011 Questcor Pharmaceuticals, Inc. (NASDAQ:  QCOR) announced today that ... to be held August 9-11, 2011 at the InterContinental Boston ... Officer, is scheduled to present an overview of the Company ... To listen to the audio web cast of ...
Cached Medicine Technology:Kensey Nash Corporation Announces Its Fourth Quarter and Fiscal Year End 2011 Earnings Release Date and Teleconference 2Questcor Pharmaceuticals to Present at the Canaccord Genuity Growth Conference on August 11, 2011 2
(Date:3/29/2015)... “Health is an endo thing, from within,” opened ... the cannabinoid system … we learn it’s where health ... Update ~ new on the Bryan William Brickner ... The Cannabis Papers: A citizen’s guide to cannabinoids (2011), ... system (CS) articles discussing: cannabinoids in the treatment of ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 Take a ... system kicks into action. Acids tumble into the stomach, ... a faulty valve-like structure lets these acids run amok, ... an extremely common symptom. More than 60 million Americans ... slides examine where heartburn starts, and how it can ...
(Date:3/28/2015)... March 28, 2015 India Network ... is made available to all visitors who purchase the ... All members are encouraged to purchase the insurance program ... lack of proper coverage for pre-existing medical conditions. Parents ... or two medical conditions with serious consequences to their ...
(Date:3/28/2015)... NV (PRWEB) March 28, 2015 How ... is a growing field in orthopaedic medicine. While diagnostic ... tear to confirm the pain etiology, research presented today ... AOSSM ) Specialty Day suggests that pain relief from ... arthroscopic hip surgery. , “Our study looked to ...
(Date:3/28/2015)... March 28, 2015 Lately the ... regarding recent changes and proposals around the NCAA. In ... and former collegiate student-athletes across a spectrum of universities ... on common challenges. The special panel consists of athletes ... sports ranging from football, track and field, baseball, and ...
Breaking Medicine News(10 mins):Health News:March Homeostasis: Publius’ Go Endo-Cannabinoid Update ~ New on the Bryan William Brickner Blog 2Health News:Bypass Your Heartburn Worries This Easter With Tylers Coffee 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 3
... world-leading publisher of medical information products and services, announced ... (PUMP) it has donated over 5,000 books to medical ... is supported by the Development Centre for Medical Science ... is in line with the spirit of the healthcare ...
... difference, report finds , THURSDAY, Oct. 8 (HealthDay News) -- ... , A new report finds that health-care costs, quality ... depending on where you live. And compared with two years ... The findings come from a state-by-state scorecard on health care ...
... Oct. 8 LeVOCC, Inc. today announced that independent laboratory ... successfully destroys a strain of the H1N1 virus. Testing ... the H1N1 virus. This strain is an influenza A ... H1N1 strains. , The LeVOCC air purification system treats indoor ...
... Quality and Health Council Calls for Greater Surface Disinfection to Combat ... cough without covering your mouth while standing in the lunch line? ... morning bus? Nearly all Americans (96 percent) have seen you ... percent) say they are guilty themselves. , Even with heightened ...
... ... (STEMCELL), a Vancouver-based life sciences company, announces the launch of MethoCult® Express, an ... only 7 days of culture. , ... Vancouver, British Columbia (PRWEB) October 8, 2009 ...
... ... Products®, a leading direct-to-consumer provider of premium dietary supplements, announces the release of ... ... Purity Products ®, a leading direct-to-consumer provider of premium dietary supplements, announces the ...
Cached Medicine News:Health News:Elsevier's Health Sciences Division and Peking University Medical Press cooperate on book donation 2Health News:Health Care Varies From State to State 2Health News:Swine Flu (H1N1) Virus Destroyed by Innovative Air Treatment Technology 2Health News:Gross Germ-Spreading Behaviors Remain the Norm, Despite Flu Season Concerns 2Health News:Gross Germ-Spreading Behaviors Remain the Norm, Despite Flu Season Concerns 3Health News:STEMCELL Technologies Inc. Introduces MethoCult Express for Cord Blood Banks and Transplant Centers 2Health News:Purity Products Releases Their Brand New Mediterranean Diet Resveratrol Formula 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: